Member Info for Ducati2

https://clinicaltrials.gov/ct2/history/NCT04385095?A=1&B=2&C=Side-by-Side#StudyPageTop

https://www.nbcnews.com/health/health-news/help-way-how-u-s-will-turn-tide-pandemic-2021-n1250353

A common approach to treating viruses is to give treatments as early as possible, when there's a lesser amount of virus in the body, making it easier for drugs to vanquish it. It's why, for example, the antiviral drug Tamiflu is meant to be given within 48 hours of a person coming down with the flu.
But drugs like this — which could prevent people from being hospitalized in the first place — are in very limited supply for Covid-19.

https://eu.usatoday.com/story/news/health/2020/12/10/covid-news-pfizer-vaccine-review-california-texas/3870677001/

Prion25..........Look we have our very own Taskforce!

The COVID-19 Therapeutics Taskforce

https://www.gov.uk/government/groups/the-covid-19-therapeutics-taskforce#contact-details

Shareholders with interests of over 3% (Significant Shareholders), as advised to the Company, are listed to the right.
In so far as the Company is aware, the percentage of the Company’s issued share capital that is not in public hands is 2.2%, which comprises the directors’ beneficial holdings of 2.2%.
0
Name of shareholder Number of ordinary shares % of share capital
Polar Capital LLP
17,500,000 8.8%
Tikvah Management LLC
8,045,000
4.0%

Taken from an RNS a couple of years ago from Synairgen, to try a give some idea of cost.

? COPD is the 3rd leading cause of death worldwide (after heart attack and stroke)5
? US national medical costs attributable to COPD and its consequences were estimated at
$32 billion in 2010 and are forecast to increase to $49 billion in 20206
? More than 15 million Americans have COPD7
? In 2010 there were 715,000 hospitalisations for COPD in the USA8
? The average cost of a hospitalisation in 2010 for a COPD patient was $7,4009

https://twitter.com/WhiteHouse/status/1336407268120797190

https://www.dvidshub.net/video/774305/covid-19-therapeutics

Tommy SG018 details below the SG016 trial..............But we will require an RNS stating trial starting date. Must be soon.

https://www.clinicaltrialsregister.eu/ctr-search/search?query=+sNG001+covid-19

https://www.synairgen.com/wp-content/uploads/2020/10/Synairgen-FR-presentation-for-Website.pdf

Synairgen selects Parexel Biotech for global study to evaluate interferon beta compound.

In the past, we’ve always run our own clinical trials, working with hospitals and research centers,” said Richard Marsden, Chief Executive Officer for Synairgen. “In the case of the SG018 trial, however, there is a clear need to find a global partner to ensure a smooth, fast, and successful trial. We look forward to working with Parexel Biotech as we progress this potential breakthrough therapy for COVID-19 patients.”

Shareholders with interests of over 3% (Significant Shareholders), as advised to the Company, are listed to the right.
In so far as the Company is aware, the percentage of the Company’s issued share capital that is not in public hands is 2.2%, which comprises the directors’ beneficial holdings of 2.2%.
0
Name of shareholder Number of ordinary shares % of share capital
Polar Capital LLP
14,791,135 7.4%
Tikvah Management LLC
8,045,000
4.0%

https://www.thearmchairtrader.com/helium-one-coral-products-synairgen/

Synairgen [LON:SNG] made in onto the list yesterday following the rally, but with no supporting news today, the stock again receives our notable mention having slipped 11%. It may be one of the biggest fallers but it’s also important to bear in mind that the applications for their technologies go well beyond COVID.

It’s trying !

Don’t think the Donald did much to help the situation.

https://www.nytimes.com/live/2020/12/07/world/covid-19-coronavirus

Shareholders with interests of over 3% (Significant Shareholders), as advised to the Company, are listed.
In so far as the Company is aware, the percentage of the Company’s issued share capital that is not in public hands is 2.2%, which comprises the directors’ beneficial holdings of 2.2%.
0
Name of shareholder Number of ordinary shares % of share capital
Polar Capital LLP
14,791,135 7.4%
Tikvah Management LLC
8,045,000
4.0%

Dibs really, with all those post you have just realised that..............You know it not a P&D!

Well got my Driver ready for a hole in ONE first thing in the morning.

GLA

https://www.fda.gov/advisory-committees/advisory-committee-calendar

12/10/2020 09:00 AM EST 12/10/2020 06:00 PM EST Vaccines and Related Biological Products Advisory Committee December 10, 2020 Meeting Announcement - 12/10/2020 - 12/10/2020 Center for Biologics Evaluation and Research

https://www.dailymail.co.uk/health/article-9026685/Nurse-took-Pfizers-coronavirus-vaccine-trial-said-highest-fever-life.html